Roche Holdings AG (OTC:RHHBY) reported follow-up efficacy, safety, and patient-reported outcomes data from the Phase 2 CITYSCAPE trial of tiragolumab plus Tecentriq as an initial treatment for PD-L1-positive metastatic non-small cell lung cancer. 

• After 2.5 years median follow-up, tiragolumab/Tecentriq combo regime continued to show an improvement in the intention-to-treat (ITT) population (n=67).
• The combination reduced the risk of disease worsening or death (progression-free survival; PFS) by 38% (median PFS=5.6 vs. 3.9 months with Tecentriq alone.
• The combo treatment improved overall response rates (ORR) (38.8% vs. 20.6%). 
• A predefined exploratory analysis in the PD-L1-high population showed a 71% reduction in the risk of disease worsening or death (median PFS=16.6 vs. 4.1 months) and a clinically meaningful improvement in ORR (69% vs. 24.1%) with the combination compared with Tecentriq alone.
• The analysis also showed that tiragolumab plus Tecentriq improved overall survival (OS), 23.2 vs. 14.5 months.
• Price Action: RHHBY shares closed at $50.47 on Thursday.